The week of June 18-24 produced four concurrent shifts in how MedTech companies will interact with Latin American regulators. Brazil moved decisively into a digitally accountable regulatory regime; Mexico published its most concrete operational guidance yet on equivalence-based registration; Colombia closed a long-running classification ambiguity for rehabilitation devices; and Argentina escalated post-market vigilance over high-value surgical instruments.
Brazil · Mexico · Colombia · Argentina
The week of June 18-24 produced four concurrent shifts in how MedTech companies will interact with Latin American regulators. Brazil moved decisively into a digitally accountable regulatory regime; Mexico published its most concrete operational guidance yet on equivalence-based registration; Colombia closed a long-running classification ambiguity for rehabilitation devices; and Argentina escalated post-market vigilance over high-value surgical instruments. Together, the announcements compress submission cycles for compliant manufacturers and raise the cost of operating outside the formal channel.
ANVISA published Resolução-RE nº 2.486 and 2.487 in the DOU on June 22, 2026, advancing the agency's parallel-review and reliance program. Days earlier, the agency issued Resolução-RE nº 2.436 (June 18, 2026), which makes uploading instructions for use (IFU) into ANVISA's documentary repository mandatory within 30 calendar days of any new device registration, notification, or update to an existing dossier. The obligation rests on RDCs 751/2022, 830/2023 and 585/2021 and applies immediately. In parallel, ANVISA opened Edital de Chamamento Público 4/2026 on June 23, soliciting industry input to modernize tecnovigilance rules, with comments due July 16, 2026.
Why It Matters: Manufacturers that have been deferring labeling-translation work or treating IFU loading as a post-launch task now face a 30-day clock that begins at DOU publication. The chamamento, by contrast, is the first formal opportunity in two years for sponsors to influence Brazil's adverse-event reporting thresholds and timelines.
COFEPRIS published a comprehensive guide on June 20, 2026 detailing requirements for sanitary registration of medical devices in Class I, II and III, including a dedicated section for software as a medical device. The guide formalizes the documentation expected when sponsors invoke the equivalence-agreement pathway with FDA, Health Canada and Japan's PMDA, and provides class-specific verification checklists covering legal representation, sanitary responsible-person designation, label projects, free-sale certificates and good manufacturing practice documentation.
What to Focus On: Sponsors holding US 510(k) clearances, Health Canada licenses or PMDA approvals can now build the equivalence dossier against an explicit COFEPRIS checklist rather than reverse-engineering it from prior submissions. The guide also clarifies the SaMD information set — functionality, indication, version, programming language, platform, interoperability and use environment — which had previously been a source of clarification cycles.
The INVIMA Sala Especializada de Dispositivos Médicos y Reactivos de Diagnóstico In Vitro published Acta No. 9 on June 19, 2026, formally classifying kinesiology tape, hand exercisers and several physiotherapy and sports-medicine products as Class I medical devices under Decree 4725 of 2005. Manufacturers and importers received a six-month grace period to obtain the corresponding sanitary certifications. INVIMA also published Circular 500-3206-16 on June 20 detailing the product-exhaustion procedure for sponsors whose registrations are mid-renewal.
Bottom Line: The reclassification removes the regulatory grey zone that had let several rehabilitation-product categories enter Colombia as consumer goods. Distributors of these products without an INVIMA registro sanitario should treat December 19, 2026 as a hard deadline; the Circular's exhaustion pathway is now the only legal route for residual stock.
ANMAT published Disposición 3753/2026 in the Boletín Oficial on June 22, 2026, prohibiting the use, commercialization and distribution of five Stryker surgical instruments — drill chuck 6203131000, Hudson/Trinkle accessory 6203135000, sagittal saw 7208000000, dual-trigger rotary handpiece 8205000000 and an associated hammer — after Stryker's Argentine subsidiary reported them missing from a consignment bank at Hospital Italiano de Buenos Aires. The disposition was reinforced by a parallel INVIMA Colombia advisory on Stryker Triathlon TS Plus knee implant components with packaging defects.
Why It Matters: ANMAT's loss-of-control order operates as a cross-border ban; chain-of-custody verification is now part of the import documentation set for orthopedic distributors moving consigned stock into Argentina. The simultaneous INVIMA action on a related Stryker line increases the probability of multi-country coordinated alerts on traceability lapses through the rest of 2026.
The 30-day IFU upload window in Brazil shifts the cost of late documentation from the post-market team to the regulatory submission timeline, requiring earlier translation and version-control planning.
Mexico's equivalence guide crystallizes a year of policy signaling into an actionable checklist — sponsors with FDA, Health Canada or PMDA clearances now hold an explicit fast-track option.
Colombia's six-month grace period on rehabilitation devices is the shortest compliance runway INVIMA has issued for a Class I reclassification this cycle, signaling tighter enforcement appetite into 2027.
Cross-border vigilance coordination is intensifying: a single missing-inventory notification triggered a national-prohibition order in Argentina alongside a separate INVIMA action in Colombia within the same week.
Operating without an authorized representative in any of these four jurisdictions has measurably more exposure than it did 30 days ago.
Need Help Navigating LATAM Regulatory Pathways? bioaccess® provides market access services with U.S. regulatory anchoring and Latin American execution — from device registration to commercial launch. Visit bioaccessla.com/market-access
← All LATAM Regulatory Dispatch editions · Contact bioaccess®